Korean circulation journal · 2026
PDE4D Mediates the Cardiac Ischemia Reperfusion Injury and Is m6A Modified by METTL14.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Beibei, Liu Hui
Аннотация
BACKGROUND AND OBJECTIVES: Cardiac ischemia-reperfusion (I/R) injury is a major contributor to morbidity following myocardial infarction. While PDE4D has been implicated in cerebral I/R injury, its role and regulatory mechanisms in the cardiac context remain unclear.
METHODS: PDE4D expression was analyzed using quantitative polymerase chain reaction and Western blot. Apoptosis was assessed by TUNEL staining, flow cytometry, and detection of caspase-3, Bax, and Bcl-2 levels. N6-methyladenosine (m6A) modification of PDE4D was examined via methylated RNA immunoprecipitation, luciferase reporter assays, and RNA stability measurements. The interaction between IGF2BP1 and PDE4D was confirmed by RNA immunoprecipitation.
RESULTS: PDE4D was significantly upregulated in I/R-injured myocardium and in H9c2 cardiomyocytes subjected to hypoxia/reoxygenation. Knockdown of PDE4D reduced infarct size, suppressed apoptosis, and improved cell viability. METTL14 mediated m6A methylation at 2 conserved sites within PDE4D mRNA, thereby enhancing its RNA stability. Silencing METTL14 decreased PDE4D expression and reduced its transcript stability. IGF2BP1 recognized m6A-modified PDE4D and promoted its RNA stability; ablation of IGF2BP1 abolished the effects of METTL14. Overexpression of PDE4D reversed the cardioprotective effects resulting from METTL14 silencing.
CONCLUSIONS: METTL14 stabilizes PDE4D mRNA through m6A methylation, which is recognized by IGF2BP1, thereby exacerbating cardiac I/R injury.
METHODS: PDE4D expression was analyzed using quantitative polymerase chain reaction and Western blot. Apoptosis was assessed by TUNEL staining, flow cytometry, and detection of caspase-3, Bax, and Bcl-2 levels. N6-methyladenosine (m6A) modification of PDE4D was examined via methylated RNA immunoprecipitation, luciferase reporter assays, and RNA stability measurements. The interaction between IGF2BP1 and PDE4D was confirmed by RNA immunoprecipitation.
RESULTS: PDE4D was significantly upregulated in I/R-injured myocardium and in H9c2 cardiomyocytes subjected to hypoxia/reoxygenation. Knockdown of PDE4D reduced infarct size, suppressed apoptosis, and improved cell viability. METTL14 mediated m6A methylation at 2 conserved sites within PDE4D mRNA, thereby enhancing its RNA stability. Silencing METTL14 decreased PDE4D expression and reduced its transcript stability. IGF2BP1 recognized m6A-modified PDE4D and promoted its RNA stability; ablation of IGF2BP1 abolished the effects of METTL14. Overexpression of PDE4D reversed the cardioprotective effects resulting from METTL14 silencing.
CONCLUSIONS: METTL14 stabilizes PDE4D mRNA through m6A methylation, which is recognized by IGF2BP1, thereby exacerbating cardiac I/R injury.